The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~The use of a~~ A compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, ~~in the preparation of a composition~~ for inhibition of kinase activity:



(I)

wherein

Ring A is an optionally substituted carbocyclic or heterocyclic radical,

Alk represents an optionally substituted divalent C_1-C_6 alkylene radical;

n is 0 or 1 ;

Q represents a radical of formula $-(Alk^1)_p-(X)_r-(Alk^2)_s-Z$ wherein in any compatible combination

Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring,

Alk^1 and Alk^2 are optionally substituted divalent C_1-C_6 alkylene radicals which may contain a -O-, -S- or $-NR^A-$link, wherein R^A is hydrogen or C_1-C_6 alkyl,

X represents -O-, -S-, -(C=O)-, -(C=S)-, -SO_2-, -SO-, -C(=O)O-, -OC(=O)-, -C(=O)NR^A-, .NR^AC(=O)-, -C(=S)NR^A-, -NR^AC(=S)-, -SO_2NR^A., -$NR^A$$SO_2$-, -OC(=O)$NR^A$-, -$NR^A$C(=O)O-, or -$NR^A$- wherein R^A is hydrogen or C_1-C_6 alkyl, and

p, r and s are independently 0 or 1,

R_1 represents a radical -$(Alk^3)_a$-$(Y)_b$-$(Alk^4)_d$-B wherein a, b and d are independently 0 or 1,

Alk^3 and Alk^4 are optionally substituted divalent C_1-C_3 alkylene radicals,

Y represents a monocyclic divalent carbocyclic or heterocyclic radical having from 5 to 8 ring atoms, -O-, -S-, or-NR^A- wherein R^A is hydrogen or C_1-C_6 alkyl,

B represents hydrogen or halo, or an optionally substituted monocyclic carbocyclic or heterocyclic ring having from 5 to 8 ring atoms, or in the case where Y is -NR^A- and b is 1, then R^A and the radical-$(Alk^4)_d$-B taken together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring,

R represents hydrogen, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkylthio, phenyl, benzyl, cycloalkyl with 3 to 6 ring atoms, or a monocyclic heterocyclic group having 5 or 6 ring atoms.

2. (Currently Amended) The ~~use~~ compound as claimed in claim 1 wherein ring A is an optionally substituted monocyclic aryl or heteroaryl radical.

3. (Currently Amended) The ~~use~~ compound as claimed in claim 2 wherein ring A is phenyl, naphthyl, 2-, 3- and 4-pyridyl, 5-pyrimidinyl, 2- and 3-thienyl, 2- and 3-furyl, piperazinyl, pyrrolidinyl, or thiazolinyl.

4. (Currently Amended) The ~~use~~ compound as claimed in claim 1 wherein ring A is phenyl.

5. (Currently Amended) The ~~use~~ compound as claimed in ~~any of the preceding claims~~ claim 1 wherein ring A is unsubstituted or substituted by methyl, ethyl, methylenedioxy, ethylenedioxy, methoxy, ethoxy, methylthio, ethylthio, hydroxy, hydroxymethyl, hydroxyethyl, mercapto, mercaptomethyl, mercaptoethyl, amino, mono- or di-methylamino, mono- or di-ethylamino, fluoro, chloro, bromo, cyano, N-morpholino, N-piperidinyl, or N-piperazinyl, the latter being optionally C_1-C_6 alkyl- or benzyl-substituted on the free ring nitrogen, dimethylaminosulfonyl, phenylsulfonyl or phenoxy.

6. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 3~~ claim 1 wherein Q is hydrogen and the ring A is 4-(dimethylaminosulfonyl)-phenyl, 4-(phenylsulfonyl)-phenyl, 4-(phenoxy)-phenyl, 3-chloro-4-(dimethylaminosulfonyl)-phenyl, 3-chloro-4(phenylsulfonyl)-phenyl, 3-chloro-4-(phenoxy)-phenyl, 3-methoxy-4(dimethylaminosulfonyl)-phenyl, 3-methoxy-4-(phenylsulfonyl)-phenyl, or 3-methoxy-4-(phenoxy)-phenyl.

7. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 5~~ claim 1 wherein n is 1 and Alk is CH_2-, $-CH_2CH_2$-, $-CH_2CH(CH_3)$-, $-CH_2CH_2CH_2$-, -CH=CH-, $-CH_2CH$=CH-, $-CH_2CH$=$CHCH_2$-, -CH=CHCH=CH-, -C=C-, $-CH_2C$=C-, or $-CH_2C$=CCH_2-.

8. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 5~~ claim 1 wherein n is 1 and Alk is $-CH_2$-.

9. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 5~~ claim 1 wherein n is 0.

10. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 5~~ claim 1 wherein each of p, r and s is 0, and Z is hydrogen.

11. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 5~~ claim 1

wherein p, r and s are each 0, and Z is an optionally substituted monocyclic carbocyclic or heterocyclic ring.

12. (Currently Amended) The ~~use~~ compound as claimed in claim 11 wherein Z is an optionally substituted phenyl, cyclopentyl, cyclohexyl, pyridyl, morpholino, piperidinyl, or piperazyl ring.

13. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 5~~ claim 1 wherein one or more of p, r and s is 1, and Z is hydrogen or an optionally substituted monocyclic carbocyclic or heterocyclic ring.

14. (Currently Amended) The ~~use~~ compound as claimed in claim 13 wherein p, ~~and/or~~ s, or both are each 1 and r is 0.

15. (Currently Amended) The ~~use~~ compound as claimed in claim 13 wherein each of p, r, and s is 1.

16. (Currently Amended) The ~~use~~ compound as claimed in claim 13 wherein p and s are each 0 and r is 1.

17. (Currently Amended) The ~~use~~ compound as claimed in claim 16 wherein X is $-SO_2-$, -O-, a sulfonamide radical $-NR^ASO_2-$ or a carboxamide radical $-NR^AC(=O)-$ with the N atom linked to the ring A.

18. (Currently Amended) The ~~use~~ compound as claimed in claim 13 wherein p is 0, r is 1, s is 1 or 0, and X is a sulfonamide radical $-NR^ASO_2-$ or a carboxamide radical $-NR^AC(=O)-$ with the N atom linked to the ring A.

19 (Currently Amended) The ~~use~~ compound as claimed in claim 17 ~~or claim 18~~ wherein R^A is hydrogen or methyl.

20. (Currently Amended) The ~~use~~ compound as claimed in claim 18 ~~or claim 19~~ wherein s is 1 and Z is hydrogen.

21. (Currently Amended) The ~~use~~ compound as claimed in claim 18 or ~~claim 19~~ wherein s is 0 and Z is an optionally substituted monocyclic carbocyclic or heterocyclic ring.

22. (Currently Amended) The ~~use~~ compound as claimed in claim 21 wherein Z is optionally substituted phenyl.

23. (Currently Amended) The ~~use~~ compound as claimed in ~~any of the preceding claims~~ claim 1 wherein in the radical R_1 a, b and d are all 0.

24. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 22~~ claim 1 wherein in the radical R_1 a and d are each 0 and b is 1.

25. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 22~~ claim 1 wherein in the radical R_1 b is 0 and at least one of a and d is 1.

26. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 23 to 25~~ claim 23 wherein in the radical R_1, B is an optionally substituted monocyclic carbocyclic or heterocyclic ring.

27. (Currently Amended) The ~~use~~ compound as claimed in claim 26 wherein B is an optionally substituted cyclopentyl, cyclohexyl, phenyl, 2-,3-, or 4-pyridyl, 2-, or 3-thienyl, 2-, or 3-furanyl, pyrrolyl, pyranyl, or piperidinyl ring.

28. (Currently Amended) The ~~use~~ compound as claimed in claim 27 wherein optional substituents are selected from methyl, ethyl, methoxy, ethoxy, methylenedioxy, ethylenedioxy, methylthio, ethylthio, hydroxy, hydroxymethyl, hydroxyethyl, mercapto, mercaptomethyl, mercaptoethyl, amino, mono- and di-methylamino, mono- and di-ethylamino, fluoro, chloro, bromo, cyano, N-morpholino, N-piperidinyl, N-piperazinyl.

29. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 22~~ claim 1 wherein R_1 is optionally substituted cyclohexyloxy; cyclohexylamino; cyclohexylmethyl, or piperidin-1ylmethyl.

30. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 22~~ claim 1 wherein R_1 is 4-aminocyclohexyloxy; 4-aminocyclohexylamino; 4-hydroxycyclohexylamino, 4-aminocyclohexylmethyl, or 4-aminopiperidin-1-ylmethyl.

31. (Currently Amended) The ~~use~~ compound as claimed in ~~any of the preceding claims~~ claim 1 wherein R is hydrogen, chloro, bromo methyl, ethyl, n-propyl, iso-propyl, n-, sec- or tert-butyl, methoxy, methylthio, ethoxy, ethylthio, or a phenyl, benzyl, cyclopropyl, cyclopentyl, cyclohexyl, 2-, 3-, or 4- pyridyl, phenyl, pyridyl, morpholino, piperidinyl, or piperazyl ring.

32. (Currently Amended) The ~~use~~ compound as claimed in ~~any of claims 1 to 30~~ claim 1 wherein R is chloro, bromo, cyclopentyl, cyclopropyl or isopropyl.

33. (Currently Amended) The ~~use~~ compound as claimed in claim 1 wherein in the compound of formula (I) n is 0, ring A is optionally substituted phenyl, Q is dimethylaminosulfonyl, phenylsulfonyl or phenoxy; R^1 is 4-aminocyclohexyloxy, 4aminocyclohexylamino, 4-hydroxycyclohexylamino, 4-aminocyclohexylmethyl, or 4-aminopiperidin-1-ylmethyl, and R is chloro, bromo, cyclopentyl, cyclopropyl or isopropyl.

34. (Currently Amended) A method of treatment of diseases or conditions mediated by excessive or inappropriate kinase activity in mammals~~, particularly humans, which method comprises~~ comprising administering to the mammal an amount of a compound of formula (I) as defined in ~~any of the preceding claims~~claim 1, or a salt, hydrate or solvate thereof, effective to inhibit said kinase activity.

35. (Canceled)

36. (Currently Amended) The ~~use as claimed in any of claims 1 to 33, a~~ method as claimed in

claim 34, ~~or a compound for use as claimed in claim 35,~~ wherein the kinase activity is CDK2 activity, ~~and/or~~ PDK1 activity, ~~and/or~~ CHK1 activity, or combinations thereof.

37. (Currently Amended) The ~~use as claimed in any of claims 1 to 33, a~~ method of treatment as claimed in claim 34, ~~or a compound for use as claimed in claim 35~~ wherein the kinase activity is associated with cancer, psoriasis or restenosis.

38. (Currently Amended) A pharmaceutical composition comprising a compound of formula (I) as defined in ~~any of claims 1 to 32~~claim 1, or a salt, N-oxide, hydrate or solvate thereof, together with a pharmaceutically acceptable carrier.

39. (Currently Amended) A compound of formula (I), or a salt, N-oxide, hydrate or solvate thereof,



(I)

wherein n is 0, ring A is optionally substituted phenyl, Q is dimethylaminosulfonyl, phenylsulfonyl or phenoxy, R^1 is 4-aminocyclohexyloxy; 4-aminocyclohexylamino; 4-hydroxyyclohexylamino; 4-aminocyclohexylmethyl, or 4-aminopiperidin-1-ylmethyl, and R is chloro, bromo, cyclopentyl, cyclopropyl or isopropyl.

40 (Currently Amended) A pharmaceutical composition as claimed in ~~claim 38 or~~ claim 39 together with a pharmaceutically acceptable carrier.